Telfast 180 180 mg TABLETS
PDF Leaflet Revision Date: 11 May 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Relief of symptoms associated with chronic idiopathic urticaria and seasonal allergic rhinitis.
Dosage (summary)
One 180 mg tablet daily for adults and children aged 12 years and over.
Onset of Action / Duration
Onset: 1 hour, Duration: 24 hours
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended during pregnancy or breastfeeding.
Key Drug Interactions
- Erythromycin
- Ketoconazole
- Aluminium and magnesium hydroxide antacids
Contraindications
- Hypersensitivity to fexofenadine or inactive ingredients
Common side effects
- Headache
- Drowsiness
- Dizziness
- Nausea
Counselling Points
- May cause drowsiness in some individuals
- Avoid alcohol and CNS depressants
Serious warnings
- Limited data in elderly and renally/hepatically impaired patients
- Potential for tachycardia and palpitations
Important Disclaimer
The Telfast 180 180 mg TABLETS professional information leaflet below is the property of Sanofi-Aventis South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
